<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3980912</article-id><article-id pub-id-type="publisher-id">1745-6215-14-S1-P45</article-id><article-id pub-id-type="doi">10.1186/1745-6215-14-S1-P45</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Biochemical efficacy and safety trial of vitamin D (BEST-D): finding an appropriate dose to test in a large randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Armitage</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Hin</surname><given-names>Harold</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Tomson</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Lay</surname><given-names>Mike</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Hill</surname><given-names>Mike</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Clarke</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Oxford, Oxford, UK</aff><aff id="I2"><label>2</label>Hightown Surgery, Banbury, UK</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2013</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">2nd Clinical Trials Methodology Conference: Methodology Matters</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the 2nd Clinical TrialsMethodology Conference.</named-content></supplement><fpage>P45</fpage><lpage>P45</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Armitage et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Armitage et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/14/S1/P45"/><conference><conf-date>18-19 November 2013</conf-date><conf-name>2nd Clinical Trials Methodology Conference: Methodology Matters</conf-name><conf-loc>Edinburgh, UK</conf-loc></conference></article-meta></front><body><sec><title/><p>Understanding the shape and strength of risk factor associations with disease in observational studies is essential for the successful design of risk factor-modification trials. Observational studies show that low plasma levels of 25-hydroxy vitamin D (25[OH]D), a blood marker of vitamin D status, are linearly related with bone mineral density and fractures, in addition to higher risks of vascular and non-vascular mortality. Over the last 20 years, several trials of vitamin D3 have assessed the effects of supplementation with equivalent daily doses of 400-800 IU on risk of fracture, but results have been conflicting. A meta-analysis of such trials reported a 14% (95%CI 4-23%) reduction in non-vertebral fractures, but the results suggest that plasma levels of 25[OH]D need to be at least 80-90 nmol/L to provide fracture protection. Moreover, previous trials also indicate an average increase of only about 7-10 nmol/L in plasma 25[OH]D for each 400 IU of vitamin D3 given daily. Consequently, at least 2000 IU daily may be required to increase plasma levels of 25(OH)D from an average winter level of 30 nmol/L (typical in the UK) to 90 nmol/L, suggesting that the previous trials have used insufficient doses of vitamin D3 to detect the epidemiologically predicted differences in clinical outcomes. To help determine the optimum dose of vitamin D3 for prevention of fractures and other health outcomes, we are comparing the biochemical efficacy and safety of 2000 and 4000 IU daily (versus placebo) vitamin D3 in a pilot study of 305 healthy people aged &#x0003e;65 years.</p></sec></body></article>